However, how NEK2 involves in NPC development remains to be elucidated. In this study, we firstly identified NEK2, located at +1q32‐q33, a late event in NPC pathogenesis, overexpressed in the stage III‐IV and paired sequential recurrent patients with NPC by immunohistochemistry. This evidence concerns the gene NEK2 and nasopharyngeal carcinoma.